drugset / Trial / NCT01611688
First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Europe. The aim of this trial is to describe the safety and tolerability of single intravenous (i.v.) and subcutaneous (s.c.) doses of NNC0215-0384 in subjects with active rheumatoid arthritis (RA) on background methotrexate (MTX) treatment.
Timeline
- Start
- 2012-06-04
- Primary completion
- 2013-06-17
- Completion
- 2013-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avdoralimab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Avdoralimab | Monoclonal antibody | 10 mg/kg | Intravenous |